COMPANY INFO
Gallant is a private biotechnology company founded in 2018 by Aaron Hirschhorn. It specializes in developing a pet health technology platform that provides stem cell therapy and regenerative medicine to treat pets by leveraging their natural biology to avoid traditional medications and surgeries. The company is headquartered in San Diego, California, and has approximately 50 employees. Gallant's mission is to make regenerative care more accessible and effective for pets, helping to extend their healthy years. Their website is https://www.gallant.com. The industry focus is Biotechnology, specifically veterinary regenerative medicine. Aaron Hirschhorn was the founder and CEO until his passing in 2021, and the current CEO is Dr. Linda Black, DVM, PhD.
Gallant Pet, Inc. is a biotechnology company specializing in veterinary regenerative medicine, focused on stem cell therapy and regenerative solutions for pets. By leveraging pets’ natural biology, Gallant aims to reduce dependency on conventional medications and surgeries, making advanced regenerative care accessible and transformative for animal health.
Gallant Pet, Inc. executives bring deep expertise across biotechnology, veterinary medicine, finance, and operations, positioning the company as a leader in pet health technology. The Gallant leadership team combines clinical, scientific, and entrepreneurial backgrounds, driving clinical innovation, scalable manufacturing, and strong financial growth while continuing the founders’ mission to extend the healthy years of pets through science-driven therapies.
As CEO, Dr. Linda Black leads Gallant Pet, Inc.’s strategic vision, accelerating its path to FDA-approved off-the-shelf stem cell therapies for pets. By overseeing the completion of Series A financing and advancing Gallant’s R&D pipeline, Dr. Black has forged critical veterinary partnerships and has played a pivotal role in the company’s national expansion.
Dr. Black is a co-founder of Gallant, previously serving as President & Chief Scientific Officer. She holds a DVM from UC-Davis and a PhD in Regenerative Medicine from Stanford University, and brings years of leadership experience in veterinary stem cell research and publication to Gallant executives.
As CTO, Dr. Carolyn Wrightson directs translational science and product development at Gallant Pet, Inc. She led the creation of Gallant’s proprietary cell isolation platform, enabling a 30% reduction in production costs and robust scale-up of therapeutic products.
Dr. Wrightson holds a PhD in Cellular Biology from MIT and completed postdoctoral work at Harvard Medical School. With 15 years in biotech, including leadership at BlueCell Biotech and CellGenix, Dr. Wrightson enhances Gallant’s management team with world-class process and product development expertise.
Steve Bach manages all financial operations, investor relations, and capital strategy for Gallant Pet, Inc. He structured the high-profile $18M Series A financing round and implemented financial systems supporting a fivefold increase in company size, ensuring fiscal discipline and scalable growth.
Mr. Bach holds an MBA from Wharton. His two-decade career in biotech finance includes CFO roles at PetHealth Diagnostics and NutriVet Pharmaceuticals, specializing in fundraising, M&A, and long-term financial planning as a core element of the Gallant leadership team.
Dr. Valentine Williams oversees clinical trial design and regulatory strategy, securing fast-track IND designation for Gallant’s lead therapies and coordinating expansive multi-site clinical studies. Dr. Williams’s regulatory acumen has significantly accelerated Gallant’s route to market.
She is a Cornell-trained DVM and MS with board certification in surgery (ACVS). Dr. Williams’s past roles at VetInnovate and BioVet Inc. in clinical and regulatory leadership underpin her expertise in veterinary biologics and strengthen Gallant's management team.
Beau Becker established and scaled Gallant’s GMP stem cell banking facility, facilitating a tenfold expansion of production capacity and implementing operating protocols that achieved perfect GMP compliance. As a founding team member, Becker plays a critical role in ensuring operational integrity.
A University of Oregon graduate, Becker has 8 years of biotech operations leadership, previously managing cell manufacturing at BioBank Labs and guiding operations at CellThera Solutions. His expertise is foundational to Gallant’s operational excellence and innovation.
Dr. Rebecca Windsor leads veterinary outreach and clinical site support for Gallant Pet, Inc., developing education programs that have boosted trial enrollment and partnered clinics. Her work ensures robust industry adoption of Gallant’s regenerative medicine protocols.
Dr. Windsor holds a DVM from the University of Pennsylvania and is a DACVIM-certified specialist with clinical and consulting experience at MidAtlantic Equine Center and VetCare Innovations, solidifying the clinical expertise among Gallant Pet, Inc. executives.
Dr. Nopmanee Taechangam advances Gallant’s preclinical research, optimizing efficacy assays and animal models to enhance stem cell candidate selection and performance. Her immunogenicity and potency assay developments have improved success rates for new therapeutics.
Dr. Taechangam holds a DVM and MS from Chulalongkorn University and a PhD from Kyoto University. With a research background at VetStem Technologies and a decade of publication credits, she drives foundational innovation for Gallant leadership.
April Treadwell oversees budgeting, reporting, and grant management, implementing financial systems that have improved efficiency and accuracy across the board. Her stewardship supports sound capital deployment and streamlined financial operations.
Ms. Treadwell holds an MBA from Stanford and brings previous experience from senior financial planning roles at AnimalRx Biotech and PetGuard Health, contributing ten years of biotech finance knowledge to Gallant's management team.
Teymour Boutros-Ghali advises on Gallant Pet, Inc. corporate governance and strategic alliances, playing an instrumental role in international growth and board-level decision-making. He guided key partnerships and co-development efforts, enhancing the company’s reach.
An MBA graduate from INSEAD and serial biotech founder, Mr. Boutros-Ghali previously oversaw investments at BioVentures Capital, serving on boards of multiple life-science companies, deepening leadership expertise for Gallant executives.
As Co-Founder, Aaron Hirschhorn established the initial vision, secured seed financing, and structured Gallant’s commercialization roadmap for stem cell therapies. He helped shape the team’s investment network and initial go-to-market strategies, laying the groundwork for the Gallant management team.
Mr. Hirschhorn’s background spans biotech venture investment (MS Finance, MIT), founding TechBio Ventures, and orchestrating early-stage financing for high-growth biotech startups, cementing his place among Gallant founders and leaders.
Gallant Pet, Inc.’s leadership team seamlessly integrates scientific innovation, clinical expertise, and business acumen, creating a balanced structure that drives sustained growth and clinical excellence. Gallant’s executives, including its CEO, scientific founders, and domain-specific directors, coordinate closely to advance the company mission, with robust oversight from an experienced board and deep-rooted founders’ vision. This collaborative and multidisciplinary approach underpins Gallant's trajectory as a pioneer in veterinary regenerative medicine.
Websets is a powerful natural language search and data enrichment tool that helps you research executive teams for any company. Whether you're analyzing the Gallant Pet, Inc. leadership team or exploring management structures at other organizations, Websets provides comprehensive insights into executive backgrounds, roles, and team dynamics.
With Websets, you can access detailed executive team profiles, management structures, and leadership insights through intuitive natural language queries. Sign up now to enhance your executive team research capabilities.